10 mg and 20 mg tablets have been approved for marketing in the United States by the Food and Drug Administration. Methylphenidate, the active ingredient of Methylin, is the leading pharmacotherapy for the treatment of ADHD, with years of proven efficacy and safety.
Greater flexibility helps ensure patient compliance and better therapeutic outcomes.
Methylin ER has an eight-hour duration of action, although behavioral efficacy is assessed most accurately on an individual patient basis. The extended release formulation is a therapeutic option when dosing schedules are problematic or when children feel stigmatized by having to take medication at school. Core symptoms include inattention, hyperactivity, and impulsivity, which may lead to school difficulties, academic underachievement, troublesome interpersonal relationships with family and peers, and low self-esteem. Nervousness and insomnia are the most common adverse reactions to methylphenidate. Additional effects may include, but are not limited to, skin rash, loss of appetite, dizziness, and headache.